NZ241463A - Treatment/diagnosis of tumours with a complex of certain metals with hydroxyethyl ethylenediamine triacetic acid - Google Patents

Treatment/diagnosis of tumours with a complex of certain metals with hydroxyethyl ethylenediamine triacetic acid

Info

Publication number
NZ241463A
NZ241463A NZ241463A NZ24146392A NZ241463A NZ 241463 A NZ241463 A NZ 241463A NZ 241463 A NZ241463 A NZ 241463A NZ 24146392 A NZ24146392 A NZ 24146392A NZ 241463 A NZ241463 A NZ 241463A
Authority
NZ
New Zealand
Prior art keywords
treatment
tumours
diagnosis
complex
triacetic acid
Prior art date
Application number
NZ241463A
Other languages
English (en)
Inventor
David A Wilson
R Keith Frank
Joseph R Garlich
Jaime Simon
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of NZ241463A publication Critical patent/NZ241463A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electroluminescent Light Sources (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ241463A 1991-01-30 1992-01-30 Treatment/diagnosis of tumours with a complex of certain metals with hydroxyethyl ethylenediamine triacetic acid NZ241463A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/648,663 US5308606A (en) 1991-01-30 1991-01-30 Method of treating and/or diagnosing soft tissue tumors

Publications (1)

Publication Number Publication Date
NZ241463A true NZ241463A (en) 2000-01-28

Family

ID=24601702

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ241463A NZ241463A (en) 1991-01-30 1992-01-30 Treatment/diagnosis of tumours with a complex of certain metals with hydroxyethyl ethylenediamine triacetic acid

Country Status (17)

Country Link
US (1) US5308606A (enExample)
EP (1) EP0499098B1 (enExample)
JP (1) JPH05505629A (enExample)
KR (1) KR100219965B1 (enExample)
AT (1) ATE216266T1 (enExample)
AU (1) AU650944B2 (enExample)
CA (1) CA2060332A1 (enExample)
DE (1) DE69232554T2 (enExample)
FI (1) FI924363A7 (enExample)
IE (1) IE920311A1 (enExample)
IL (1) IL100800A (enExample)
MX (1) MX9200413A (enExample)
NZ (1) NZ241463A (enExample)
SG (1) SG45366A1 (enExample)
TW (1) TW205509B (enExample)
WO (1) WO1992013571A1 (enExample)
ZA (1) ZA92663B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
WO2001028592A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
AU785505B2 (en) 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
WO2002055530A2 (en) * 2000-10-25 2002-07-18 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
AU2002322275A1 (en) * 2001-06-20 2003-01-08 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US20060074034A1 (en) * 2001-09-17 2006-04-06 Collins Douglas A Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
KR100440725B1 (ko) * 2002-06-20 2004-07-15 주식회사 그린진 바이오텍 비생물성 스트레스에 대한 단자엽 식물의 내성을증가시키는 방법
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US7419654B2 (en) * 2004-10-08 2008-09-02 Mrinal K. Dewanjee Charge neutral complexes of paramagnetic metals as intracellular magnetic resonance imaging contrast agents
EP1893038A1 (en) * 2005-05-17 2008-03-05 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US421452A (en) * 1890-02-18 Island
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
EP0176288B1 (en) * 1984-09-21 1990-05-09 The Dow Chemical Company Aminocarboxylic acid complexes for the treatment of calcific tumors
NZ222304A (en) * 1987-05-18 1990-10-26 Dow Chemical Co Suppression of bone marrow using samarium-153, gadolinium-159 or holmium-166 complexes

Also Published As

Publication number Publication date
IL100800A (en) 1996-10-31
ATE216266T1 (de) 2002-05-15
KR930700163A (ko) 1993-03-13
IL100800A0 (en) 1992-09-06
CA2060332A1 (en) 1992-07-31
EP0499098A3 (en) 1992-08-26
FI924363L (fi) 1992-09-29
ZA92663B (en) 1993-07-30
DE69232554T2 (de) 2002-08-08
FI924363A0 (fi) 1992-09-29
JPH05505629A (ja) 1993-08-19
AU650944B2 (en) 1994-07-07
FI924363A7 (fi) 1992-09-29
MX9200413A (es) 1992-08-01
US5308606A (en) 1994-05-03
KR100219965B1 (ko) 1999-09-01
EP0499098B1 (en) 2002-04-17
AU1054392A (en) 1992-08-06
IE920311A1 (en) 1992-07-29
TW205509B (enExample) 1993-05-11
SG45366A1 (en) 1998-01-16
WO1992013571A1 (en) 1992-08-20
EP0499098A2 (en) 1992-08-19
DE69232554D1 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
NZ241463A (en) Treatment/diagnosis of tumours with a complex of certain metals with hydroxyethyl ethylenediamine triacetic acid
PH31049A (en) Bicyclopolyazamacrocy clophosphonic acid complexesfor use as radiopharmaceuticals.
CA2453845A1 (en) Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
WO1997017446A3 (en) HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ZA989150B (en) Mouth hygienic composition for the treatment of halitosis
GR3035717T3 (en) Tie-2 ligands, methods of making and uses thereof
CA2115249A1 (en) Phosphopeptides for the treatment of dental calculus
NO20016427L (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
WO1993009762A3 (en) Method for extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
AU4299496A (en) Novel multiple-substituent dtpa derivatives and metal complexes thereof, pharmaceutical compositions containing such complexes, their use in diagnosis and therapy, methods ofpreparing the complexing agents and complexes and methods of preparing the pharmaceutical compositions
AU5314694A (en) New agents for diagnosis of vascular diseases
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
PT1488806E (pt) Anticorpo monoclonal bloqueador contra vla-1 e sua utilização no tratamento de distúrbios vasculares
CA2116829A1 (en) Use of a pregnane derivative
EP1532162A4 (en) HUMANIZED ANTI-DAY-72 CC49 FOR DIAGNOSIS AND THERAPY HUMAN TUMORS
IL141936A0 (en) Antibodies to c3b(1) for delivery of diagnostic and therapeutic agents to cancer cells
JPH11513374A (ja) （放射性）標識化ビオチン誘導体類
WO1997047329A3 (en) Radiopharmaceutical compositions capable of localizing at sites of thrombus
AU2215099A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
EP1440163A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF PAIN DISEASES USING 46566
TW374018B (en) Composition for treating renal failure
HUP9902664A2 (hu) Jelzett biotinszármazékok, eljárás e vegyületek előállítására, valamint e vegyületeket tartalmazó gyógyászati készítmények, ilyen készítmény előállítására szolgáló készlet, továbbá eljárás tumorok detektálására és lokalizálására
Robb-Nicholson By the way, doctor. I am 47 and have been taking Loestrin 1/20 for the past seven months. After the first month, I ceased having periods, which my gynecologist says is typical. Could you comment on why this happens and whether I am putting myself at increased risk for uterine cancer?
RU93054509A (ru) Комплексы бициклополиазамакроциклофосфоновой кислоты их получение, конъюгаты, фармацевтические композиции - набор для диагностики и лечения

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)